welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
MDA Releases Duchenne Fact Sheet, Survey Results Pointing to Need for Knowledge of Clinical Trials and Genetic Tests
Citing a persistent need for new treatments and patient support, the Muscular Dystrophy Association (MDA) has updated its Duchenne muscular dystrophy (DMD) fact sheet.
In related news, two top issues identified in a landmark MDA-funded survey of neuromuscular disease families were access to quality care along with a greater knowledge of genetic testing and clinical trials.
The fact sheet is intended for use by DMD families, patients’ teachers, and care providers, and includes an overview of Duchenne as well as its symptoms, treatment choices, essential facts and a terms glossary.
Its release was timed with Duchenne Muscular Dystrophy Awareness Week, Feb. 13–18, a news release said. The three-page guide notes, for example, that Duchenne affects 1 in 5,000 newborn boys, and that, owing to advances in cardiac and respiratory care, their life expectancy is generally increasing.
rareRelated
-
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy PatientsThis study is designed to assess the eff...
-
Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophyThe aim of this multicentre, prospective...
-
A Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
-
Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMDThis study will collect MRI from healthy...
-
Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)Duchenne/Becker muscular dystrophy (DMD/...
-
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
-
A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyThe objective of this study is to evalua...
-
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical TrialCapricor Therapeutics announced today th...
-
An Update on Clinical Trial Innovation for Duchenne – a Master Protocol SharePPMD is committed to making research and...
-
Design of a phase 3 trial to evaluate the long-term efficacy and safety of ataluren in patients with nonsense mutati...Ataluren is conditionally approved by th...
-
Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial For Edasalonexent In Duchenne Muscular Dystrop...Catabasis Pharmaceuticals, Inc., a clini...
